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Figure 1 Detection of NTRK1 Arg774Pro mutation in an HSAN IV patient. A, Pedigree of the family analyzed in this work. Blackened
symbols denote patients with HSAN IV homozygous for the 774 mutation (proband); half-blackened symbols denote unaffected individuals
heterozygous for the 774 mutation; unblackened symbols denote unaffected individuals homozygous for the wild-type NTRK1 sequence; slashed
symbols denote unexamined individuals. Individual II-1 is reported to have insensitivity to pain. B, Sequence analysis of NTRK1 exon 17 in
the proband family. Exon 17 was amplified from genomic DNA by PCR with primers 17F (5′-GGACTGGCCTCACTCTCTTG-3′) and 17R
(5′-GTCATCCCAATAACTGGCAAG-3′). The amplified fragments were subjected to nucleotide sequence with an ABI Prism 377 DNA sequencer
(Perkin-Elmer). The proband (V-1) shows a GrC transversion at nucleotide 2405 (codon 774); individual III-2 displays the wild-type sequence;
in all other family members a mix of C and G (S, according to the International Union of Biochemistry code) is detected at position 2405.
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A Novel NTRK1 Mutation Associated with Congenital
Insensitivity to Pain with Anhidrosis
To the Editor:
Among the hereditary sensory and autonomic neuro-
pathies (HSAN), type IV (HSAN IV), also known as
congenital insensitivity to pain with anhidrosis (CIPA;
MIM 256800), is a rare autosomal recessive disorder
clinically characterized by loss of pain sensitivity, self-
mutilating behavior, unexplained episodes of fever, an-
hidrosis, and mental retardation (Rosemberg et al. 1994;
Axelrod 1996). Ultrastructural and morphometric stud-
ies of the peripheral nerves reveal loss of unmyelinated
and small myelinated fibers and no innervation of sweat
glands (Langer et al. 1981; Axelrod and Pearson 1984).
These features suggest that a defect in the differentiation
and migration of neuronal crest elements and a possible
deregulation of the NGF/NTRK1 pathway may be re-
sponsible for CIPA. It has been reported recently that
the NTRK1/NGF receptor gene is implicated in the path-
ogenesis of CIPA (Kaplan et al. 1991; Klein et al. 1991;
Smeyne et al. 1994; Fagan et al. 1996); point mutations
within its tyrosine kinase (TK) domain have been de-
tected in four patients with consanguinous parents (Indo
et al. 1996). We have recently reported that one of those
mutations, a GlyrArg substitution at codon 571, exerts
a loss-of-function effect (A. Greco, R. Villa, L. Fusetti,
V. Ranzi, R. Orlandi, andM. Pierotti, unpublished data).
We have shown that the NTRK1 TK activity and bio-
logical effects are abolished when the Gly571Arg mu-
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Figure 2 Biochemical and biological analysis of TRK-T3 and NTRK1 proteins carrying the Arg774Pro mutation. A, Expression and
phosphorylation of wild-type (wt) andmutated proteins. wt andmutated TRK-T3 andNTRK1 cDNAswere cloned into the pRC/CMVexpression
vector. COS1 cell transfection and western blot analysis were performed as described elsewhere (Greco et al. 1998). Two different TRK-T3
mutated clones are shown (T3/774 a and b). Cells transfected with the NTRK1 constructs were treated with NGF (50 ng/ml) for 10 min before
extraction. B, In vitro immunocomplex kinase assay. wt, ATP-binding negative (ABN; Greco et al. 1998), 774, and 571 (A. Greco, R.Villa, L.
Fusetti, V. Ranzi, R. Orlandi, and M. Pierotti, unpublished data) mutant TRK-T3 proteins transiently expressed into COS1 cells were immu-
noprecipitated with anti-TRK antibody and blotted with the same antibody (left) or subjected to immunocomplex-kinase assay (right). In the
latter, two replicates for each sample are shown. C, Transforming activity of T3/774 protein. NIH3T3 cells were transfected with 500 ng of
the indicated plasmid DNA by the calcium phosphate precipitation method, using 30 mg HMW NIH3T3 DNA as carrier. Transfected cells were
selected in a G418-containing medium or in a 5% serum medium. G418-resistant colonies and transformed foci were fixed and stained after
selection for 2 weeks. Both constructs produced an equivalent number of G418-resistant colonies.
tation is introduced into both the NTRK1 receptor and
the constitutively active TRK-T3 oncogene (Greco et al.
1995).
Here we report the detection of a novel NTRK1 mu-
tation associated with CIPA and demonstrate its inac-
tivating effect. An Italian CIPA patient and his family
(fig. 1) were screened for NTRK1 mutations. All the
NTRK1 exons were amplified by PCR from peripheral
blood lymphocite–DNA and sequenced by an ABI Prism
377 DNA sequencer (Perkin-Elmer). As a control, Hela
DNA was amplified and sequenced simultaneously. A
homozygous GrC transversion at nucleotide 2405
(exon 17, ArgrPro substitution at amino acid 774) was
detected in the proband. All the other members of the
family, including a younger, unaffected brother, are het-
erozygous, except for the paternal grandmother, who is
homozygous for the wild-type sequence. Interestingly,
the Arg774Pro mutation was present in both maternal
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grandparents, who had no documented consanguinity
but were both from the same village.
To ascertain that the Arg774Pro mutation, rather than
a rare polymorphism, was the cause of CIPA in the fam-
ily, we performed functional studies, as reported for the
Gly571Arg mutation (A. Greco, R. Villa, L. Fusetti, V.
Ranzi, R. Orlandi, and M. Pierotti, unpublished data),
in an attempt to unveil a loss-of-function effect. The
Arg774Pro mutation was introduced into the constitu-
tively active TRK-T3 oncogene and the wild-type
NTRK1 receptor cDNAs (Greco et al. 1995) by site-
directed mutagenesis. The mutated constructs (T3/774
and NTRK1/774) express protein of the expected mo-
lecular weight, as deduced by western blot analysis with
anti-TRK antibodies (fig. 2A). Immunoblotting with
antiphosphotirosine antibodies showed that the
Arg774Pro mutation abrogates the constitutive phos-
phorylation of the TRK-T3 oncogene and the NGF-me-
diated phosphorylation of the wild-type NTRK1 recep-
tor (fig. 2A). We analyzed the in vitro TK activity of
mutant T3/774 with an immunocomplex autokinase as-
say. Two kinase-defective mutants (T3/ABN [Greco et
al. 1998] and T3/571 [A. Greco, R. Villa, L. Fusetti, V.
Ranzi, R. Orlandi, and M. Pierotti, unpublished data])
and the wild-type construct were used as negative and
positive controls, respectively. As shown in figure 2B,
the amounts of all the proteins were similar; the T3/774
and two kinase-defective mutants display an undetect-
able level of phosphorylation activity. In the NIH3T3
transfection/focus formation assay, no transformed foci
arose from NIH3T3 cells transfected with T3/774 (fig.
2C), indicating that the introduced mutation abrogates
the TRK-T3 transforming activity. All these findings
demonstrate the loss-of-function effect of the Arg774Pro
mutation, analogous to what was reported for the
Gly571Arg mutation (A. Greco, R.Villa, L. Fusetti, V.
Ranzi, R. Orlandi, and M. Pierotti, unpublished data).
In conclusion, we have detected the following novel
NTRK1 mutation associated with CIPA: a GrC trans-
version at nucleotide 2405 causing an ArgrPro substi-
tution at codon 774. Biological and biochemical studies
are consistent with a loss-of-function effect, demonstrat-
ing the pathogenic role of this mutation. Arg 774 is
located at the C terminus of the NTRK1 TK domain; it
is surrounded by residues conserved among the different
members of TRK receptor family, but it is present only
in NTRK1. Its role in receptor activation is unknown.
However, our data outline the importance of such res-
idues for NTRK1 activity. It is interesting to note that
all reported mutations associated with HSAN IV occur
within the NTRK1 TK domain. Other point mutations
occurring in the extracellular portion of NTRK1 or mu-
tations of other genes encoding neurotrophin receptors
might cause other variants of HSAN.
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Mutations in the RP2 Gene Cause Disease in 10% of
Families with Familial X-Linked Retinitis Pigmentosa
Assessed in This Study
To the Editor:
X-linked retinitis pigmentosa (XLRP; MIM 312600) is
a severe form of retinal degeneration that typically pre-
sents as loss of the peripheral visual field and night blind-
ness in affected males within the 1st or 2d decade of life,
owing to primary degeneration of rod photoreceptor
cells and bone spicule pigmentary deposits (Bird 1975).
The disease is progressive: loss of central vision occurs
later in life, and complete functional blindness often oc-
curs by 40–50 years of age. RP2 was the first genetically
mapped retinitis pigmentosa (RP) locus (Bhattacharya
et al. 1984) and showed disease segregation with the
RFLP detected by the probe L1.28 (DXS7). Subsequent
genetic-mapping studies have shown exceptional genetic
heterogeneity for autosomal RP and XLRP, which is
illustrated on the short arm of the X chromosome
and on RP2, RP3, RP15, and RP23 (Ott et al. 1990;
McGuire et al. 1995; Thiselton et al. 1996; A. J. Hard-
castle, D. L. Thiselton, T. S. Mah, M. B. Gorin, and
S. S. Bhattacharya, unpublished data). Extensive ho-
mogeneity and heterogeneity analyses of worldwide
XLRP family collections suggested that RP3 (frequency
70%–75%) and RP2 (frequency 20%–25%) are the pre-
dominant forms (Ott et al. 1990; Teague et al. 1994).
The RP3 gene was positionally cloned, facilitated by the
identification of submicroscopic deletions in affected pa-
tients (Meindl et al. 1996; Roepman et al. 1996). The
causative gene, a putative guanine-nucleotide-exchange
factor (RPGR), appears to be mutated in only 15%–
20% of patients with XLRP (Meindl et al. 1996; Roep-
man et al. 1996; Buraczynska et al. 1997), not the
70%–75% expected from the results of genetic-mapping
studies (Teague et al. 1994). Investigation of splice var-
iants, promoter/enhancer mutations, and as yet uniden-
tified exons may account for the low mutation rate de-
tected in this gene; however, a more likely explanation
for these findings is microheterogeneity. In comparison,
genetic mapping suggested that RP2 is rare (15%–20%
of patients with XLRP), and the close proximity to RP3,
together with a lack of disease-associated deletions, has
hampered the search for the RP2 gene for many years.
We reported haplotype analysis for two pedigrees, which
defined both proximal and distal boundaries of the RP2
critical interval to a region of 5 cM between DXS8083
(Xp11.3) and DXS6616 (Xp11.23) (Thiselton et al.
1996) and which excluded the candidate gene TIMP1
(Hardcastle et al. 1997b). The RP2 gene recently has
been positionally cloned by targeting this interval by use
of the YAC representation hybridization technique
(Schwahn et al. 1998). RP2 consists of five exons,
encodes a polypeptide of 350 amino acids, and is
ubiquitously expressed. The predicted amino acid se-
quence has homology to cofactor C, over 151 amino
acids (30.4%), which is involved in b-tubulin folding
(Schwahn et al. 1998). Currently, this provides the only
functional clue for the RP2 gene; hence, the overall func-
tion and specific role in the retina are unknown at pres-
ent. We have screened our panel of patients with XLRP
for mutations in the RP2 gene, to define the spectrum
of mutations causing disease. Of particular interest were
the two definitive genetically defined families with RP2
that we had described previously (families F72 andNRP;
Thiselton et al. 1996).
Appropriate informed consent was obtained from pa-
tients and relatives. Of a total of 59 families with XLRP
assessed in this study, 26 families were excluded from
RP2 gene mutation screening, because haplotype and
linkage analyses excluded the RP2 interval or because
RPGR mutations had already been identified. The re-
maining 33 families with XLRP were assessed for RP2
mutations.
DNA from affected male patients from each of the 33
pedigrees (and two normal male controls) was amplified
with primer pairs described by Schwahn et al. (1998),
by use of 150 ng of initial template DNA and withminor
modifications to the suggested annealing temperatures
(details available on request from the authors). Purified
PCR products (8 ml of product incubated with 1 U
shrimp alkaline phosphatase [SAP; Amersham Life Sci-
ence] and 1 U Exonuclease I [United States Biochemical]
in SAP buffer, at 37C for 30 min followed by 80C for
15 min) were aliquoted (5 ml) for cycle sequencing in
the forward and reverse directions, by use of the ABI
Prism Ready Reaction Dye Terminator cycle sequencing
kit (fluorescent sequencing kit, Perkin-Elmer), in accor-
dance with the manufacturer’s instructions. Reactions
then were electrophoresed on an ABI 373A automated
sequencer.
Segregation of the mutation, with the disease, was
